Cardiac Magnetic Resonance Imaging

  • Róisín Morgan
  • Raymond Y. KwongEmail author
Part of the Contemporary Cardiology book series (CONCARD)


Heart disease is the leading cause of deaths in the United States. Every year approximately 735,000 Americans suffer a myocardial infarction (MI). Of these, 525,000 are a first MI, and 210,000 occur in people who have known CAD and a history of prior MI. Approximately 5.7 million adults in the United States have a diagnosis of heart failure. It is estimated that in 2010, over two million infants, children, adolescents, and adults were living with congenital heart disease (CHD) in the United States, and the number is ever-increasing as surgical approaches for underlying CHD and medical treatments improve. An estimated 2.7–6.1 million people in the United States have atrial fibrillation. With the aging of the US population, this number is expected to increase. Each of these cardiac conditions can be evaluated with cardiac MRI, either as a baseline diagnostic tool or as a therapeutic roadmap as in the case of atrial and ventricular arrhythmias. With its increasing clinical availability, improved duration scan times (under 1 h), and lack of ionizing radiation, CMR is an excellent tool for the evaluation of cardiac structure and function in most cardiac patients.


Myocardial infarction Noninvasive Conditions Protocols MRI 

Supplementary material

Video 27.1

Two-, three-, and four-chamber cine images (MOV 6448 kb)

Video 27.2

Four-chamber SSFP view . The large mass is clearly seen in the right atrium (gray structure in RA invading the interatrial septum) (MOV 844 kb)

Video 27.3

Four-chamber tagging : tag lines highlight the size and location of the RA mass and indicate the relationship between different tissue planes, useful in determining the degree of mass invasion into surrounding structures (MOV 693 kb)

Video 27.4

Cardiac CT which was helpful in this case to create a 3D image of the mass and its relationship to surrounding structures, including blood supply (MOV 12372 kb)

Video 27.5

The post-gadolinium axial navigator sequence which highlights the size and location of the mass and its relationship to surrounding structures and indicates a necrotic core to the mass that was not appreciated prior to gadolinium administration (MOV 4397 kb)


  1. 1.
    Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. Natl Vital Stat Rep. 2013;64(2):1–119.Google Scholar
  2. 2.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update. Circulation. 2015;131(4):e29–e322.Google Scholar
  3. 3.
    Gilboa SM, Devine OJ, Kucik JE, Oster ME, Riehle-Colarusso T, Nembhard WN, Xu P, Correa A, Jenkins K, Marelli AJ. Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation. 2010;134(2):101–9.CrossRefGoogle Scholar
  4. 4.
    Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, et al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. J Cardiovasc Magn Reson. 2004;6(4):727–65.CrossRefGoogle Scholar
  5. 5.
    Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J. 2004;25(21):1940–65.CrossRefGoogle Scholar
  6. 6.
    Hendel RC, Patel MR, Kramer CM, Poon M, Carr JC, Gerstad NA, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol. 2006;48(7):1475–97.CrossRefGoogle Scholar
  7. 7.
    Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Rosenbaum L, Shaw LJ, Stainback RF, Allen JM. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease. J Card Fail. 2014;20(2):65–90.CrossRefGoogle Scholar
  8. 8.
    Patel MR, White RD, Abbara S, et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. J Am Coll Cardiol. 2013;61(21):2207–31. Scholar
  9. 9.
    Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;55(23):2614–62.CrossRefGoogle Scholar
  10. 10.
    Ripley DP, Saha A, Teis A, Uddin A, Bijsterveld P, Kidambi A, McDiarmid AK, Sivananthan M, Plein S, Pennell DJ, Greenwood JP. The distribution and prognosis of anomalous coronary arteries identified by cardiovascular magnetic resonance: 15 year experience from two tertiary centres. J Cardiovasc Magn Reson. 2014;16(1):34.CrossRefGoogle Scholar
  11. 11.
    Pazos-López P, Pozo E, Siqueira ME, García-Lunar I, Cham M, Jacobi A, Macaluso F, Fuster V, Narula J, Sanz J. Value of CMR for the differential diagnosis of cardiac masses. JACC Cardiovasc Imaging. 2014;7(9):896–905. Scholar
  12. 12.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212–60. Scholar
  13. 13.
    Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Circulation. 2010;121(13):1533–41.CrossRefGoogle Scholar
  14. 14.
    Marcotte F, Poirier N, Pressacco J, Paquet E, Mercier LA, Dore A, Ibrahim R, Khairy P. Evaluation of adult congenital heart disease by cardiac magnetic resonance imaging. Congenit Heart Dis. 2009;4(4):216–30. Scholar
  15. 15.
    Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, et al. Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging. 2015;8(6):pii: e003073.CrossRefGoogle Scholar
  16. 16.
    Higgins CB, Herfkens R, Lipton MJ, Sievers R, Sheldon P, Kaufman L, et al. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol. 1983;52(1):184–8.CrossRefGoogle Scholar
  17. 17.
    Carlsson M, Ubachs JF, Hedstrom E, Heiberg E, Jovinge S, Arheden H. Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging. 2009;2(5):569–76.CrossRefGoogle Scholar
  18. 18.
    Abdel-Aty H, Cocker M, Meek C, Tyberg JV, Friedrich MG. Edema as a very early marker for acute myocardial ischemia: a cardiovascular magnetic resonance study. J Am Coll Cardiol. 2009;53(14):1194–201.CrossRefGoogle Scholar
  19. 19.
    Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992–2002.CrossRefGoogle Scholar
  20. 20.
    Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445–53.CrossRefGoogle Scholar
  21. 21.
    Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation. 2001;104(10):1101–7.CrossRefGoogle Scholar
  22. 22.
    Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110(12):1535–41.CrossRefGoogle Scholar
  23. 23.
    Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008;118(10):1011–20.CrossRefGoogle Scholar
  24. 24.
    Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114(1):32–9.CrossRefGoogle Scholar
  25. 25.
    Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113(23):2733–43.CrossRefGoogle Scholar
  26. 26.
    Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33–9.CrossRefGoogle Scholar
  27. 27.
    Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8(3):543–7.CrossRefGoogle Scholar
  28. 28.
    Westwood MA, Sheppard MN, Awogbade M, Ellis G, Stephens AD, Pennell DJ. Myocardial biopsy and T2* magnetic resonance in heart failure due to thalassaemia. Br J Haematol. 2005;128(1):2.CrossRefGoogle Scholar
  29. 29.
    Bisbal F, Guiu E, Cabanas-Grandio P, Berruezo A, Prat-Gonzalez S, Vidal B, et al. CMR-guided approach to localize and ablate gaps in repeat AF ablation procedure. JACC Cardiovasc Imaging. 2014;7(7):653–63.CrossRefGoogle Scholar
  30. 30.
    Piers SR, Tao Q, de Riva Silva M, Siebelink HM, Schalij MJ, van der Geest RJ, et al. CMR-based identification of critical isthmus sites of ischemic and nonischemic ventricular tachycardia. JACC Cardiovasc Imaging. 2014;7(8):774–84.CrossRefGoogle Scholar
  31. 31.
    Kitkungvan D, Nabi F, Ghosn MG, Dave AS, Quinones M, Zoghbi WA, et al. Detection of LA and LAA thrombus by CMR in patients referred for pulmonary vein isolation. JACC Cardiovasc Imaging. 2016;9(7):809–18.CrossRefGoogle Scholar
  32. 32.
    Parsai C, O’Hanlon R, Prasad SK, Mohiaddin RH. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson. 2012;14:54.CrossRefGoogle Scholar
  33. 33.
    Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E, Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.CrossRefGoogle Scholar
  34. 34.
    Schwitter J, Wacker CM, van Rossum AC, Lombardi M, Al-Saadi N, Ahlstrom H, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008;29(4):480–9.CrossRefGoogle Scholar
  35. 35.
    Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2007;50(14):1343–53.CrossRefGoogle Scholar
  36. 36.
    Yan AT, Gibson CM, Larose E, Anavekar NS, Tsang S, Solomon SD, et al. Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging. J Cardiovasc Magn Reson. 2006;8(6):831–7.CrossRefGoogle Scholar
  37. 37.
    Levine GN, Gomes AS, Arai AE, Bluemke DA, Flamm SD, Kanal E, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2007;116(24):2878–91.CrossRefGoogle Scholar
  38. 38.
    Edwards MB, Taylor KM, Shellock FG. Prosthetic heart valves: evaluation of magnetic field interactions, heating, and artifacts at 1.5 T. J Magn Reson Imaging. 2000;12(2):363–9.CrossRefGoogle Scholar
  39. 39.
    Li A, Wong CS, Wong MK, Lee CM, Au Yeung MC. Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates. Br J Radiol. 2006;79(941):368–71.CrossRefGoogle Scholar
  40. 40.
    Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology. 1995;196(2):439–43.CrossRefGoogle Scholar
  41. 41.
    Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359–62.CrossRefGoogle Scholar
  42. 42.
    Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4):1104–8.CrossRefGoogle Scholar
  43. 43.
    Vitti RA. Gadolinium-based contrast agents and nephrogenic systemic fibrosis. Radiology. 2009;250(3):959; author reply 959–60CrossRefGoogle Scholar
  44. 44.
    Pohost GM, Kim RJ, Kramer CM, Manning WJ. Task force 12: training in advanced cardiovascular imaging (cardiovascular magnetic resonance [CMR]) endorsed by the Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2008;51(3):404–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Brigham and Women’s HospitalBostonUSA
  2. 2.Cardiovascular Division, Department of MedicineBrigham and Women’s HospitalBostonUSA

Personalised recommendations